SURPASS-CVOT

The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT).

Study title

Background

The trial will be looking at whether using the new drug tirzepatide helps to reduce the risk of heart disease for people with type 2 diabetes, compared to dulaglutide, which is an approved diabetes medication. People with type 2 diabetes are much more likely to suffer from disease of the heart and blood vessels than adults without diabetes.

Study Aims

Previous research has confirmed that tirzepatide is effective for patients with diabetes as it lowers the amount of glucose in the red blood cells, but with the benefit of fewer side effects and can help with weight loss. Researchers now want to find out if tirzepatide can also help protect against heart disease, making it a better overall drug for patients with type 2 diabetes.

Study Summary

This international study aims to enrol 12,500 volunteers, of which 200 are expected to be in the UK, and will last for up to five or six years. Participants will have type 2 diabetes, be aged 40 or over with a history of cardiovascular disease and are overweight or obese.

Study Progress 

Actively recruiting through the NIHR Patient Recruitment Centre: Leicester.

Funding and Sponsorship 

The study is a commercial study funded and sponsored by Eli Lilly and Company Limited.

Study Publications

The study results will be published by the sponsor after study completion.

Research Team

Principal Investigator: Professor Melanie Davies

Research Nurse: Penny Donley

For more information, please contact: penelope.donley@uhl-tr.nhs.uk